William Skinner, MD
Cardiovascular Disease · Lexington, KYNPI 1447337860
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $271,630 of the $311,781 with a category attached, or 87.1%. 59 manufacturers reported payments, led by Johnson & Johnson at 29.5% of the total. Reporting peaked in 2019 at $93,719 and has fallen 97.4% since, to $2,450 in 2025. Among cardiovascular disease clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,469 payments — averaging $212.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$92K
- Amgen$83K
- Esperion Therapeutics, Inc.$67K
- Novartis$28K
- Lexicon Pharmaceuticals, Inc.$27K
- Medtronic$4K
- plus $12K from 53 others
Across 2 payments — averaging $16,993 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$34K
What the payments were for
- Consulting fees$2,3251%
- Speaking & faculty fees$271,63087%
- Travel & lodging$10,2443%
- Food & beverage$27,5829%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$88,649
- Repatha$80,971
- NEXLIZET$65,106
- NEXLETOL$65,106
- Inpefa$26,012
- ENTRESTO$24,978
- Resolute$2,479
- Indigo System$157
- PRESSUREWIRE$157
- Telescope$144
- OPTIS$132
- GENERAL - STENTS$125
- Watchman$124
- Barostim Neo System$119
- SYMPLICITY G3$119
- Assure WCD$118
- ONYX FRONTIER$112
How this compares
$311,781 in reported general payments places this provider in the 95th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 1,173 | $1,296,198 |
| EntrestoSacubitril/Valsartan | 702 | $828,687 |
| EliquisApixaban | 691 | $745,563 |
| Repatha SureclickEvolocumab | 573 | $732,372 |
| FarxigaDapagliflozin Propanediol | 97 | $116,072 |
| NexlizetBempedoic Acid/Ezetimibe | 127 | $111,746 |
| Praluent PenAlirocumab | 64 | $86,331 |
| JardianceEmpagliflozin | 72 | $78,677 |
| Ambrisentan | 27 | $76,950 |
| InpefaSotagliflozin | 46 | $46,233 |
| Ezetimibe | 1,235 | $23,169 |
| VerquvoVericiguat | 11 | $22,667 |
| MultaqDronedarone Hcl | 13 | $21,168 |
| VascepaIcosapent Ethyl | 33 | $18,944 |
| Metoprolol Succinate | 1,264 | $18,656 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $91,943 | $1,296,1981,173 claims |
| NovartisEntresto | $27,583 | $828,687702 claims |
| PfizerEliquis | $678 | $745,563691 claims |
| AstraZenecaFarxiga, Brilinta | $734 | $122,906111 claims |
| Esperion Therapeutics, Inc.Nexlizet | $66,885 | $111,746127 claims |
| Boehringer IngelheimJardiance | $367 | $78,67772 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $26,825 | $46,23346 claims |
| MerckVerquvo | $812 | $22,66711 claims |
| Sanofi-aventis U.S. LLCMultaq | $654 | $21,16813 claims |
| AmgenCorlanor | $82,846 | $8,03511 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $103 | $5,51816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Lexington
- David MoliternoLexington$115K
- Andrew LeventhalLexington$43K
- John GurleyLexington$21K
- Suresh SharmaLexington$15K
- James CragerLexington$12K
- Kevin ScullyLexington$9K
- Nathan KustererLexington$8K
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- Prabodh MehtaElizabethtown$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.